Related Experiment Video
Updated: Jan 24, 2026

Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach
Published on: December 1, 2011
HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype
Juan Berenguer1,2, José Luis Calleja3,4,5,6, María Luisa Montes7,8
1Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Insights
HIV infection predicts treatment failure in patients with chronic hepatitis C. This study found HIV-positive individuals had lower sustained viral response rates when treated with ledipasvir/sofosbuvir.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- Direct-acting antiviral (DAA) efficacy is often assumed similar for hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected patients.
- Limited data exist on HIV's impact on DAA treatment failure due to small numbers in trials.
Purpose of the Study:
- To compare treatment outcomes of ledipasvir/sofosbuvir (LDV/SOF) for HCV genotype 1 in treatment-naïve patients with and without HIV.
- To identify predictors of treatment failure in HCV patients receiving DAAs.
Main Methods:
- A prospective registry study compared outcomes for LDV/SOF in treatment-naïve, noncirrhotic patients with HCV G1.
- Included 1358 patients: 1055 HCV-monoinfected and 303 HIV/HCV-coinfected (99% on antiretroviral therapy).
Main Results:
- Sustained viral response (SVR) rates at 12 weeks were significantly lower for HIV/HCV-coinfected patients (91.8%) compared to HCV-monoinfected patients (97.2%; P = .001).
- Multivariable analysis identified male sex (aOR, 2.49) and HIV infection (aOR, 2.23) as predictors of treatment failure.
Conclusions:
- HIV infection is a significant predictor of treatment failure in patients receiving LDV/SOF for chronic hepatitis C.
- Findings suggest potential differences in DAA efficacy based on HIV coinfection status.
Background:
The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)-monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA regimens and the small number of HIV-infected patients included in registration trials have made it difficult to identify predictors of treatment failure, including the presence of HIV.
Methods:
We compared treatment outcomes for ledipasvir/sofosbuvir (LDV/SOF) against HCV G1 in treatment-naïve HCV-Mono and HCV-Co without cirrhosis in a prospective registry of individuals receiving DAAs for HCV.
Results:
Up to September 2017, a total of 17 269 patients were registered, and 1358 patients (1055 HCV-Mono/303 HCV-Co) met the inclusion criteria. Significant differences between HCV-Mono and HCV-Co were observed for age, gender, and G1 subtype distribution. Among HCV-Co, 99.0% were receiving antiretroviral therapy. SVR rates for LDV/SOF at 8 weeks did not differ significantly between HCV-Mono and HCV-Co (96.9% vs 94.0%; P = .199). However, the SVR rate for LDV/SOF at 12 weeks was significantly higher for HCV-Mono than HCV-Co (97.2% vs 91.8%; P = .001). A multivariable logistic regression model including age, sex, liver stiffness, G1 subtype, HCV-RNA, HIV, and treatment duration showed the factors associated with treatment failure to be male sex (adjusted odds ratio [aOR], 2.49; 95% confidence interval [CI], 1.27-4.91; P = .008) and HIV infection (aOR, 2.23; 95% CI, 1.13-4.38; P = .020).
Conclusions:
The results of this large prospective study analyzing outcomes for LDV/SOF against HCV G1 in treatment-naïve noncirrhotic patients suggest that HIV infection is a predictor of treatment failure in patients with chronic hepatitis C.
Related Concept Videos
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Predicting Molecular Geometry
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
End Point Prediction: Gran Plot
For potentiometric titration, the Gran plot is created by plotting...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...

